Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy (Q85893467)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 January 2013

Language	Label	Description	Also known as
English	Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy	scientific article published on 13 January 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

pancreatic cancer

1 reference

based on heuristic

inferred from title

author name string

Michael Haas

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Volker Heinemann

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Frank Kullmann

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Rüdiger P Laubender

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christina Klose

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christiane J Bruns

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stefan Holdenrieder

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Dominik P Modest

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Christoph Schulz

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Stefan Boeck

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

13 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

139

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

681-689

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23315099%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

REporting recommendations for tumour MARKer prognostic studies (REMARK)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic treatment of advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic and predictive value of serum CA19.9 in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute-phase protein response and survival duration of patients with pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modelling prognostic factors in advanced pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23315099

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85893467&oldid=2221770291"